1. Soluble mimics of the cytoplasmic face of the human V1-vascular vasopressin receptor bind arrestin2 and calmodulin. Wu N, Macion-Dazard R, Nithianantham S, Xu Z, Hanson SM, Vishnivetskiy SA, Gurevich VV, Thibonnier M, Shoham M (2006) Mol Pharmacol 70(1): 249-58
    › Primary publication · 16574744 (PubMed)
  2. Differential interaction of spin-labeled arrestin with inactive and active phosphorhodopsin. Hanson SM, Francis DJ, Vishnivetskiy SA, Kolobova EA, Hubbell WL, Klug CS, Gurevich VV (2006) Proc Natl Acad Sci U S A 103(13): 4900-5
    › Primary publication · 16547131 (PubMed) · PMC1458767 (PubMed Central)
  3. Arrestins: ubiquitous regulators of cellular signaling pathways. Gurevich EV, Gurevich VV (2006) Genome Biol 7(9): 236
    › Primary publication · 17020596 (PubMed) · PMC1794542 (PubMed Central)
  4. Arrestin binding to calmodulin: a direct interaction between two ubiquitous signaling proteins. Wu N, Hanson SM, Francis DJ, Vishnivetskiy SA, Thibonnier M, Klug CS, Shoham M, Gurevich VV (2006) J Mol Biol 364(5): 955-63
    › Primary publication · 17054984 (PubMed) · PMC1783800 (PubMed Central)
  5. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, HÃ¥kansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E (2005) Parkinsonism Relat Disord : S25-9
    › Primary publication · 15885624 (PubMed)
  6. Light-dependent redistribution of arrestin in vertebrate rods is an energy-independent process governed by protein-protein interactions. Nair KS, Hanson SM, Mendez A, Gurevich EV, Kennedy MJ, Shestopalov VI, Vishnivetskiy SA, Chen J, Hurley JB, Gurevich VV, Slepak VZ (2005) Neuron 46(4): 555-67
    › Primary publication · 15944125 (PubMed) · PMC2752952 (PubMed Central)
  7. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Bezard E, Gross CE, Qin L, Gurevich VV, Benovic JL, Gurevich EV (2005) Neurobiol Dis 18(2): 323-35
    › Primary publication · 15686961 (PubMed)
  8. Inhibition of chemoattractant N-formyl peptide receptor trafficking by active arrestins. Key TA, Vines CM, Wagener BM, Gurevich VV, Sklar LA, Prossnitz ER (2005) Traffic 6(2): 87-99
    › Primary publication · 15634210 (PubMed)
  9. Dopamine D1 receptor interaction with arrestin3 in neostriatal neurons. Macey TA, Liu Y, Gurevich VV, Neve KA (2005) J Neurochem 93(1): 128-34
    › Primary publication · 15773912 (PubMed)
  10. Crystal structure of cone arrestin at 2.3A: evolution of receptor specificity. Sutton RB, Vishnivetskiy SA, Robert J, Hanson SM, Raman D, Knox BE, Kono M, Navarro J, Gurevich VV (2005) J Mol Biol 354(5): 1069-80
    › Primary publication · 16289201 (PubMed)